Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05580861 | Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment(SALMA) | recruiting | Phase 1 / Phase 2 | 64 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06387420 | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 180 | AkesoINDUSTRY | 1 | Apr 29, 2024 |
| clinicaltrials |
| NCT03999723 | Combining Active and Passive DNA Hypomethylation(EVI-3) | recruiting | Phase 2 | 196 | Kirsten GrønbækOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT04793919 | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | recruiting | Phase 2 | 89 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 12 | Apr 15, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT05319249 | Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia(NAKIP-AML) | not yet recruiting | Phase 1 / Phase 2 | 54 | German Cancer Research CenterOTHER | 0 | Apr 5, 2024 | clinicaltrials |
| NCT06250959 | RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.(BEAT-ALL-2024) | recruiting | Phase 2 | 124 | Chen SuningOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT01686334 | Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission(WIDEA) | active not recruiting | Phase 2 | 130 | Zwi BernemanOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06046313 | Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS | recruiting | Phase 2 | 120 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06050941 | Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | not yet recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Mar 5, 2024 | clinicaltrials |
| NCT06220487 | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL(ABC) | recruiting | Phase 2 | 67 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06133556 | Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML | not yet recruiting | Phase 2 | 237 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 15, 2023 | clinicaltrials |
| NCT06125652 | Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06081478 | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 100 | Beijing Tongren HospitalOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT03825796 | CPX-351 Plus Enasidenib for Relapsed AML | active not recruiting | Phase 2 | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05931757 | A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL | not yet recruiting | Phase 2 | 22 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05805098 | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML(VHA) | recruiting | Phase 2 / Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05736965 | A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia(SAV) | recruiting | Phase 2 | 58 | Shanghai Tong Ren HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05736978 | Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results(AVS) | recruiting | Phase 2 | 58 | Shanghai Tong Ren HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05648019 | CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol | recruiting | Phase 2 | 40 | KK Women's and Children's HospitalOTHER_GOV | 1 | Mar 9, 2023 | clinicaltrials |
| NCT04499573 | Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL | active not recruiting | Phase 1 / Phase 2 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05521204 | Olverembatinib for FGFR1-rearranged Neoplasms | recruiting | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 30, 2022 | clinicaltrials |
| NCT05404906 | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | recruiting | Phase 2 / Phase 3 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT01744223 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 36 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03301168 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 120 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05445154 | SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05431257 | Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling(LD-VenEx) | recruiting | Phase 2 | 117 | Rigshospitalet, DenmarkOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05055791 | A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Sep 24, 2021 | clinicaltrials |
| NCT04746209 | Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | recruiting | Phase 2 | 25 | Medical College of WisconsinOTHER | 1 | Sep 17, 2021 | clinicaltrials |
| NCT05025098 | Precision Therapy Versus Standard Therapy in AML and MDS in Elderly(PALM) | recruiting | Phase 2 | 36 | University Hospital, AkershusOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT03709719 | Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia(GRAALL-QUEST) | active not recruiting | Phase 2 | 95 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT04451200 | Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning(BUSEQ) | not yet recruiting | Phase 2 | 82 | Institut Paoli-CalmettesOTHER | 0 | Nov 17, 2020 | clinicaltrials |
Data updated 22 days agoSource updated May 29, 2024source: clinicaltrials